Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Denmark’s Novo Nordisk scored a significant regulatory win for GLP-1 drug Wegovy (semaglutide), as the US Food and Drug ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss therapy Wegovy, allowing its use against metabolic dysfunction-associated ...

Novo Nordisk's weight-loss drug Wegovy has been approved to treat a common type of liver disease, the Food and Drug ...

Decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a liver condition that affects around 5 per cent of ...

Novo Nordisk A/S’s blockbuster weight-loss drug Wegovy received Food and Drug Administration approval to treat a serious form ...

The FDA has granted accelerated approval to Wegovy® (semaglutide) as the first treatment for MASH with moderate-to-advanced ...